The chief medical officer at Stoke Therapeutics provided commentary on the promising mechanism of action of STK-001, an antisense agent, in the treatment of Dravet syndrome. [WATCH TIME: 3 minutes]:
Source: Neurology Read More
Mechanism Behind Novel STK-001 as Disease-Modifying Treatment for Dravet Syndrome: Barry Ticho, MD, PhD
Related Posts
<![CDATA[Votoplam Shows Dose-Dependent Slowing of
Disease Progression in Stage 2 Huntington Disease]]>
<![CDATA[Votoplam Shows Dose-Dependent Slowing of Disease Progression in Stage 2 Huntington Disease]]>
